Safety and efficacy of sensor augmented insulin pump versus double C therapy in poorly controlled type 2 diabetes

Abstract

To compare the efficacy, safety and efficiency of sensor augmented insulin pump (SAP) versus double-C therapy in poorly controlled type 2 diabetes (T2DM). A total of 81 patients with T2DM, HbA1c ≥ 9%, were divided randomly into SAP or continuous subcutaneous insulin infusion and retrospective continuous glucose monitoring (double C) group for both 6 days. In both groups, mean blood glucose (MBG), mean amplitude of glycemic excursion (MAGE) and 24 h area under the curve at 10 (AUC10) significantly decreased after therapy (P < 0.05). These parameters in SAP group were lower than those in double C group (P < 0.05). No significant difference existed in 24 h area under the curve at 3.9 (AUC3.9) (P > 0.05). Compared with double C group, time spend to-blood glucose-target was shorter and in-target range proportion higher in SAP group (P < 0.05). Logistic regression analysis showed that 2 h C peptide (CP)/fasting C peptide (FCP), HbA1c and sensor alert on (all P < 0.05) were independently correlated with up-to blood glucose target. Compared with double C, SAP therapy may decrease blood glucose (BG), reduce glucose fluctuation and improve up-to target proportions without a higher risk of hypoglycemia.